Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Switzerland's Occlutech Holding. This strategic move aims to access high-value global markets. The deal is expected to finalize by June 2026. Occlutech is a key player in Europe's minimally invasive cardiac implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QRcUVtm
via IFTTT

Read More

AIIMS Delhi first in country to announce launch of face transplant programme

AIIMS New Delhi has become the first hospital in India to introduce face transplantation, a complex reconstructive procedure for patients with severe facial deformities. The Department of Plastic, Reconstructive and Burns Surgery has begun creating a patient registry and is conducting specialised training, including a cadaveric workshop, with support from international expert Dr Indranil Sinha of Harvard Medical School.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zHdnsOB
via IFTTT

Read More

HUL turns ₹70 cr bet in Wellbeing Nutrition into ₹307 cr exit

Hindustan Unilever has divested its 19.8% stake in Wellbeing Nutrition to UVS Pharma for Rs 307 crore. This move comes after HUL's initial Rs 70 crore investment in 2022. The transaction, expected to conclude by March 2026, sees Wellbeing Nutrition valued at approximately Rs 1,600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r7hxTCY
via IFTTT

Read More

Zydus settles US Mirabegron patent dispute with Astellas for $120 million

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2lCe6r
via IFTTT

Read More

USV Pharma leads race to buy 85% stake in Wellbeing Nutrition at Rs 1,600 crore valuation

The Mumbai-based brand, owned by Nutritionlab, counts Hindustan Unilever and Fireside Ventures among its early backers. HUL and Fireside — holding 19.8% stake each — will exit with more than fourfold returns. Both invested in Wellbeing Nutrition about three years ago when the company was valued at about Rs 350 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8v4k2bP
via IFTTT

Read More

Trial by fire: Novelis may see bigger cash flow hit

In the wake of a second devastating fire at its Oswego facility, Novelis Inc. has revised its expectations dramatically, now forecasting a staggering impact on its free cash flow. Originally bracing for a loss of $550-650 million, the company is now looking at potential damages between $1.3-1.6 billion prior to insurance compensation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UL1XGcu
via IFTTT

Read More

Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents

The Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Myers Squibb to halt its progress. The court has mandated that BMS verify how Zydus's product aligns with their patent claims, with options for BMS to request provisional support from the High Court following this analysis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Az5Lho8
via IFTTT

Read More